vimarsana.com
Home
Live Updates
Recommends Advancing - Breaking News
Pages:
Latest Breaking News On - Recommends advancing - Page 1 : vimarsana.com
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.
United states
Astrazeneca tagrisso
Mark berger
Genprex inc
Merck co keytruda
Drug administration
Exchange commission
Safety review committee
Recommends advancing
Increased dose
Second cohort
Fast track designation
Immunogene therapy
Chief medical officer
Nanoparticle delivery system
Private securities litigation reform act
vimarsana © 2020. All Rights Reserved.